Amanta Healthcare Ltd

Stage 2 · Advancing · week 20Setup 9.3 ★★★ PrimeStrong +0.8

As of 20 Nov 2026, Amanta Healthcare is in Stage 2, the uptrend phase, now in week 20 (since 6 Jul 2026). It closed at ₹222, 7.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 34.7% of stocks are in Stage 2.

Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin Am… More about the company

₹222.4
Close, 20 Nov 2026
-6.99% on the day
₹863 Cr · Small cap
Market DowntrendHealth Care 34.7% in Stage 2-11.4 pts / 20dPharmaceuticals 42.4%-13.9 pts

Pro read

Pro

Our read

In a healthy advance

Setup score

9.3 ★★★ Prime

RS rank

Edge

Strong +0.8

AMANTA is about 5 months into its Stage 2 advance, 16% above its 50-day average and 7% under its 52-week high. With the trend established, this middle stretch has tended to be the steadiest part of a move.

Its relative strength is 95 of 99, a leader among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.

Stocks with a similar setup at this point in their move ran 0.8 points ahead of the average stock over the next 30 sessions on average, after costs, and their typical best close within 60 sessions was 16% above entry.

The trend read holds while it stays in Stage 2. A close below ₹191, its 50-day average, would put it at rest; ₹191, 20% under its 52-week high of ₹239, is where a trailing stop would sit.

Setup-score rank among Stage 2 peers: #3 of 50 in Pharmaceuticals · #3 of 61 in Health Care

Is AMANTA early, or has it already run? Pro answers that for every NSE stock, after every close.

Loading price chart…
Stage Cycle Timeline2025-09-11 → 2026-11-20
S? 42w
S2 20w
2025-09-112026-11-20
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 20w current
Total tracked: 62 weeks across 2 stage runs.

AMANTA among Pharmaceuticals15th of 118 by relative strength

All 118 →
Stocks in Pharmaceuticals ranked by relative strength, with stage and one-month change
#StockStageRS1M
1BLISSGVSStage 2 · wk 4999+4.6%
2KPLStage 2 · wk 4499+20.5%
3FREDUNStage 2 · wk 3398+24.0%
4VENUSREMStage 3 · wk 1098−1.5%
5RUBICONStage 3 · wk 498+18.7%
6SAKARStage 2 · wk 5598+13.1%
7BAFNAPHStage 2 · wk 2398+1.9%
8INDSWFTLABStage 2 · wk 2398−7.4%
…15AMANTAStage 2 · wk 2095+38.8%
vs 52W High
-7.0%
₹95 lo₹239.1 hi
7.0% below 52W high, pullback range
How far this stock is from its 52-week high. A stock a little below its high with its Stage 2 structure intact is in a pullback, not a breakdown.
Stage Maturity
Week 20
1w13w26w
Week 20, proven structure
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
46.8%
200 DMA: ₹151.4 · rising
The stock is above its 200-day average, the long-term trend line. That is where a Stage 2 advance normally trades.
Rel Volume
1.11x
vs 50-day avg
Volume was close to average, nothing unusual. In a Stage 2 advance, look for heavy volume on breakouts and quiet volume on pullbacks.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+38.8%
3M
+25.2%
6M
+76.0%
YTD
+103.9%
1Y
+87.4%
Sector
Health Care
↓ Peaking
Stage 2%
34.7%
20d Δ
-11.4pp
1M return
+11.5%
3M return
+3.8%
Sector Stage-2 % · last 20 days
This stock ranks #15 of 58 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
42.4%
20d Δ
-13.9pp
1M return
+8.3%
3M return
+2.1%
Industry Stage-2 % · last 20 days
Ranks #12 of 48 Stage 2 stocks in this industry.
Scan Membership
In the scan on 20 Nov 2026
Last appeared 6 Jul 2026
17 appearances in the last 60 days.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-11-20S2
Wk 20 · Vol 1.11x
2026-11-19S2
Wk 19 · Vol 0.67x
2026-11-18S2
Wk 19 · Vol 1.58x
2026-11-17S2
Wk 19 · Vol 3.79x
2026-11-16S2
Wk 19 · Vol 1.98x
2026-11-13S2
Wk 19 · Vol 6.36x
2026-11-12S2
Wk 18 · Vol 32.01x
2026-11-11S2
Wk 18 · Vol 1.20x
2026-11-09S2
Wk 18 · Vol 1.26x
2026-11-06S2
Wk 18 · Vol 1.17x
2026-11-05S2
Wk 18 · Vol 3.25x
2026-11-04S2
Wk 17 · Vol 7.58x
Moving averages & range
50 DMA
₹191.2
200 DMA
₹151.4
52W High
₹239.1
52W Low
₹95
5D Low
₹220.4
Resistance levels (recent highs)
20d High
₹239.1
60d High
₹239.1
120d High
₹239.1
250d High
₹239.1
Next resistance
+7.5%
to 20d High
P/E (TTM)
56.4
Forward —
Earnings Growth (YoY)
+257.1%
Revenue +17.3%
ROE
+8.4%
Profit margin +6.0%
Dividend Yield
0.00%
P/B 4.0

Amanta Healthcare: quick answers

What stage is Amanta Healthcare in?

As of 20 Nov 2026, Amanta Healthcare (AMANTA) is in Stage 2, the uptrend phase. It entered Stage 2 on 6 Jul 2026 and is in week 20. What the four stages mean

Is Amanta Healthcare in an uptrend?

Yes. Amanta Healthcare is in a Stage 2 uptrend. It trades 46.8% above its 200-day average, which is rising.

How far is Amanta Healthcare from its 52-week high?

Amanta Healthcare closed at ₹222 on 20 Nov 2026, 7.0% below its 52-week high of ₹239. Its 52-week low is ₹95.03.

How has Amanta Healthcare performed over the past year?

As of 20 Nov 2026, Amanta Healthcare is up 87.4% over the past year and up 103.9% so far in 2026.

Which sector and industry is Amanta Healthcare in?

Amanta Healthcare is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals

About this companyHealth Care· Pharmaceuticals

Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. Amanta Healthcare Limited was formerly known as Marck Biosciences Limited and changed its name to Amanta Healthcare Limited in June 2014. Amanta Healthcare Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.